Broadline (0.6 - 2.5 kg)
Active substance
ATC code
Species
Cats
Indications
For cats with, or at risk from mixed infestations by cestodes, nematodes and ectoparasites. The veterinary medicinal product is exclusively indicated when all three groups are targeted at the same time.
Ectoparasites
- Treatment and prevention of infestations by fleas (Ctenocephalides felis). Elimination of fleas within 24 hours. One treatment prevents further infestations for at least one month.
- Prevention of environmental flea contamination by inhibiting the development of flea immature stages (eggs, larvae and pupae) for over a month.
- The product can be used as part of a treatment strategy for the control of flea allergy dermatitis (FAD).
- Treatment and prevention of infestations by ticks (Ixodes ricinus). Elimination of ticks within 48 hours. One treatment prevents further infestations for up to 3 weeks.
- Treatment of notoedric mange (Notoedres cati).
Cestodes
- Treatment of infestations with tapeworms (Dipylidium caninum, Taenia taeniaeformis, Echinococcus multilocularis , Joyeuxiella pasqualei (adult), and Joyeuxiella fuhrmanni (adult)).
Nematodes
- Treatment of infestations with gastrointestinal nematodes (L3, L4 larvae and adults of Toxocara cati, adults of Toxascaris leonina, L4 larvae and adults of Ancylostoma tubaeforme and Ancylostoma ceylanicum, and adults of Ancylostoma brazilienze).
- Treatment of infestations with feline lungworms (L3 larvae, L4 larvae and adults of Aelurostrongylus abstrusus , L4 larvae and adults of Troglostrongylus brevior).
- Treatment of infestations with vesical worms (Capillaria plica).
- Prevention of heartworm disease (Dirofilaria immitis larvae) for one month.
Dose to be administered and administration route
Spot-on use.
The use of the veterinary medicinal product should exclusively be based on the confirmed mixed infestations or significant risk of such mixed infestation with ectoparasites and nematodes (including for heartworm disease prevention) and where concurrent treatment against cestodes is indicated. In the absence of risk of co-infestation, the use of a narrow spectrum parasiticide should be considered as a first line therapy.
The rationale for prescription should be tailored to the individual needs of the cat, based on clinical assessment, the animal’s lifestyle and on the local epidemiological situation (including zoonotic risks, where relevant) in order to address exclusively situations of mixed infestations/risk of infestation.
Treatment should not be extrapolated from one animal to the other without veterinary opinion.
Dosage:
The recommended minimum doses are 10 mg/kg bodyweight for fipronil, 12 mg/kg for (S)-methoprene, 0.5 mg/kg for eprinomectin and 10 mg/kg for praziquantel.
Select the appropriate applicator size for the weight of the cat.
|
Cat weight |
Volume of unit dose (ml) |
Fipronil (mg) |
S-methoprene (mg) |
Eprinomectin (mg) |
Praziquantel (mg) |
|
< 2.5 kg |
0.3 |
25 |
30 |
1.2 |
25 |
|
2.5-7.5 kg |
0.9 |
75 |
90 |
3.6 |
75 |
|
> 7.5 kg |
appropriate combination of applicators |
||||
Method of administration:
Use a pair of scissors to cut the blister along the dotted line, then pull the lid away.
Remove the applicator from the package and hold it upright. Pull back the plunger slightly, twist and pull off the cap. Part the hair on the midline of the neck, between the base of the skull and the shoulder blades until the skin is visible. Place the tip of the applicator on the skin and apply the entire content directly onto the skin in one spot.
Prevention of heartworm disease (Dirofilaria immitis larvae) should start within 1 month after the first expected exposure to mosquitoes.
For treatment against Aelurostrongylus abstrusus, a second administration one month after the initial treatment may be recommended.
Adverse reactions
A temporary clumping or spiking of the hair and mild and transient skin reactions at the application site (itching, hair loss) have been commonly observed at the application site after treatment in clinical studies.
Temporary excessive salivation was commonly observed following licking the application site after treatment in clinical trials.
Digestive tract and/or neurological disorders may result following an accidental oral ingestion of the veterinary medicinal product (see section 4.5). Transitory blindness or impaired vision have been observed in very rare cases based on post marketing safety experience.
Symptomatic treatment can be required if the signs do not resolve spontaneously within 24 hours. Correct application will minimise the occurrence of such events (see section 4.9).
The frequency of adverse reactions is defined using the following convention:
- very common (more than 1 in 10 animals treated displaying adverse reaction(s))
- common (more than 1 but less than 10 animals in 100 animals treated)
- uncommon (more than 1 but less than 10 animals in 1,000 animals treated)
- rare (more than 1 but less than 10 animals in 10,000 animals treated)
- very rare (less than 1 animal in 10,000 animals treated, including isolated reports).
| PRICE | Only for registered vets. Create a free profile to access all features.. Login |
|---|---|
| Art. Nr. | 04491/5005 |
| EAN | 4028691570837 |
